Differential effect of age on survival in advanced NSCLC in women versus men

Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

H. A. Wakelee, S. E. Dahlberg, J. R. Brahmer, J. H. Schiller, M. C. Perry, C. J. Langer, A. B. Sandler, C. P. Belani, D. H. Johnson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.

Original languageEnglish (US)
Pages (from-to)410-415
Number of pages6
JournalLung Cancer
Volume76
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Drug Therapy
Carboplatin
Paclitaxel
Platinum
Bevacizumab
Age Groups
Therapeutics

Keywords

  • Age/sex interactions
  • Bevacizumab
  • Chemotherapy
  • NSCLC
  • Prognostic factors
  • Sex/gender differences

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Differential effect of age on survival in advanced NSCLC in women versus men : Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. / Wakelee, H. A.; Dahlberg, S. E.; Brahmer, J. R.; Schiller, J. H.; Perry, M. C.; Langer, C. J.; Sandler, A. B.; Belani, C. P.; Johnson, D. H.

In: Lung Cancer, Vol. 76, No. 3, 06.2012, p. 410-415.

Research output: Contribution to journalArticle

Wakelee, H. A. ; Dahlberg, S. E. ; Brahmer, J. R. ; Schiller, J. H. ; Perry, M. C. ; Langer, C. J. ; Sandler, A. B. ; Belani, C. P. ; Johnson, D. H. / Differential effect of age on survival in advanced NSCLC in women versus men : Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. In: Lung Cancer. 2012 ; Vol. 76, No. 3. pp. 410-415.
@article{90a6b551cd364acebf6fdb4c09fbd02c,
title = "Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab",
abstract = "Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.",
keywords = "Age/sex interactions, Bevacizumab, Chemotherapy, NSCLC, Prognostic factors, Sex/gender differences",
author = "Wakelee, {H. A.} and Dahlberg, {S. E.} and Brahmer, {J. R.} and Schiller, {J. H.} and Perry, {M. C.} and Langer, {C. J.} and Sandler, {A. B.} and Belani, {C. P.} and Johnson, {D. H.}",
year = "2012",
month = "6",
doi = "10.1016/j.lungcan.2011.12.006",
language = "English (US)",
volume = "76",
pages = "410--415",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Differential effect of age on survival in advanced NSCLC in women versus men

T2 - Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

AU - Wakelee, H. A.

AU - Dahlberg, S. E.

AU - Brahmer, J. R.

AU - Schiller, J. H.

AU - Perry, M. C.

AU - Langer, C. J.

AU - Sandler, A. B.

AU - Belani, C. P.

AU - Johnson, D. H.

PY - 2012/6

Y1 - 2012/6

N2 - Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.

AB - Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N= 1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N= 850) were similarly separated by age and sex and by treatment (±bevacizumab). Survival was calculated separately for each cohort. Results: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p= 0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p= 0.03) for women (younger had greater benefit), with no age effect in men. Conclusions: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.

KW - Age/sex interactions

KW - Bevacizumab

KW - Chemotherapy

KW - NSCLC

KW - Prognostic factors

KW - Sex/gender differences

UR - http://www.scopus.com/inward/record.url?scp=84862815339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862815339&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.12.006

DO - 10.1016/j.lungcan.2011.12.006

M3 - Article

VL - 76

SP - 410

EP - 415

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -